Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q4 and full year financial results for 2023 this afternoon.The American medical R&D powerhouse had some setbacks in the year, including disappointing profits from their drug Humira, which lost significant market share to generic knockoffs in both the US and abroad in 2023. Full year resultsCopy link to sectionThe company reported net revenues of $54.318 billion, 6.4 percent less YoY than 2022, and diluted EPS of$2.72 for the full year on a GAAP basis ...